|
1
|
Lee D, Yu YB, Choi JH, Jo AH, Hong SM, Kang JC, Kim JH. Viral Shrimp Diseases Listed by the OIE: A Review. Viruses 2022; 14:v14030585. [PMID: 35336992 PMCID: PMC8953307 DOI: 10.3390/v14030585] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 02/06/2022] [Accepted: 02/14/2022] [Indexed: 02/06/2023] Open
Abstract
Shrimp is one of the most valuable aquaculture species globally, and the most internationally traded seafood product. Consequently, shrimp aquaculture practices have received increasing attention due to their high value and levels of demand, and this has contributed to economic growth in many developing countries. The global production of shrimp reached approximately 6.5 million t in 2019 and the shrimp aquaculture industry has consequently become a large-scale operation. However, the expansion of shrimp aquaculture has also been accompanied by various disease outbreaks, leading to large losses in shrimp production. Among the diseases, there are various viral diseases which can cause serious damage when compared to bacterial and fungi-based illness. In addition, new viral diseases occur rapidly, and existing diseases can evolve into new types. To address this, the review presented here will provide information on the DNA and RNA of shrimp viral diseases that have been designated by the World Organization for Animal Health and identify the latest shrimp disease trends.
Collapse
Affiliation(s)
- Dain Lee
- Fish Genetics and Breeding Research Center, National Institute of Fisheries Science, Geoje 53334, Korea;
| | - Young-Bin Yu
- Department of Aquatic Life Medicine, Pukyong National University, Busan 48513, Korea
- Correspondence: (Y.-B.Y.); (J.-H.C.); (J.-C.K.); (J.-H.K.); Tel.: +82-41-675-3773 (J.-H.K.)
| | - Jae-Ho Choi
- Department of Aquatic Life Medicine, Pukyong National University, Busan 48513, Korea
- Correspondence: (Y.-B.Y.); (J.-H.C.); (J.-C.K.); (J.-H.K.); Tel.: +82-41-675-3773 (J.-H.K.)
| | - A-Hyun Jo
- Department of Aquatic Life and Medical Science, Sun Moon University, Asan-si 31460, Korea; (A.-H.J.); (S.-M.H.)
| | - Su-Min Hong
- Department of Aquatic Life and Medical Science, Sun Moon University, Asan-si 31460, Korea; (A.-H.J.); (S.-M.H.)
| | - Ju-Chan Kang
- Department of Aquatic Life Medicine, Pukyong National University, Busan 48513, Korea
- Correspondence: (Y.-B.Y.); (J.-H.C.); (J.-C.K.); (J.-H.K.); Tel.: +82-41-675-3773 (J.-H.K.)
| | - Jun-Hwan Kim
- Department of Aquatic Life and Medical Science, Sun Moon University, Asan-si 31460, Korea; (A.-H.J.); (S.-M.H.)
- Correspondence: (Y.-B.Y.); (J.-H.C.); (J.-C.K.); (J.-H.K.); Tel.: +82-41-675-3773 (J.-H.K.)
| |
Collapse
|
|
2
|
Ma X, Hui H, Jin Y, Dong D, Liang X, Yang X, Tan K, Dai Z, Cheng Z, Tian J. Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation. Biomaterials 2016; 87:46-56. [PMID: 26897539 DOI: 10.1016/j.biomaterials.2016.02.007] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Revised: 01/01/2016] [Accepted: 02/04/2016] [Indexed: 02/07/2023]
Abstract
SM5-1 is a humanized mouse monoclonal antibody, targeting an over-expressed membrane protein of approximately 230 kDa in hepatocellular carcinoma (HCC). SM5-1 can be used for target therapy in hepatocellular carinoma due to its ability of inhibiting cell growth and inducing apoptosis. However, the tumor inhibition efficacy of SM5-1 in HCC cancer treatment remains low. In this study, we synthesized SM5-1-conjugated gold nanoparticles (Au-SM5-1 NPs) and investigated their anticancer efficacy in HCC both in vitro and in vivo. The tumor inhibition rates of Au-SM5-1 NPs for subcutaneous tumor mice were 40.10% ± 4.34%, 31.37% ± 5.12%, and 30.63% ± 4.87% on day 12, 18, and 24 post-treatment as determined by bioluminescent intensity. In addition, we investigated the antitumor efficacy of Au-SM5-1 NPs in orthotopic HCC tumor models. The results showed that the inhibition rates of Au-SM5-1 NPs can reach up to 39.64% ± 4.87% on day 31 post-treatment determined by the bioluminescent intensity of the abdomen in tumor-bearing mice. Furthermore, three-dimensional reconstruction results of the orthotopic tumor revealed that Au-SM5-1 NPs significantly inhibited tumor growth compared with SM5-1 alone. Our results suggested that the developed Au-SM5-1 NPs has great potential as an antibody-based nano-drug for HCC therapy.
Collapse
Affiliation(s)
- Xibo Ma
- Key Laboratory of Molecular Imaging of Chinese Academy of Sciences, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China; Molecular Imaging Program at Stanford (MIPS), Bio-X Program, Department of Radiology, Stanford University, CA, 94305-5344, USA; Beijing Key Laboratory of Molecular Imaging, Beijing, 100190, China
| | - Hui Hui
- Key Laboratory of Molecular Imaging of Chinese Academy of Sciences, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China; Beijing Key Laboratory of Molecular Imaging, Beijing, 100190, China
| | - Yushen Jin
- Nanomedicine and Biosensor Laboratory, School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China
| | - Di Dong
- Key Laboratory of Molecular Imaging of Chinese Academy of Sciences, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China; Beijing Key Laboratory of Molecular Imaging, Beijing, 100190, China
| | - Xiaolong Liang
- Department of Biomedical Engineering, College of Engineering, Peking University, Beijing, 100871, China
| | - Xin Yang
- Key Laboratory of Molecular Imaging of Chinese Academy of Sciences, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China; Beijing Key Laboratory of Molecular Imaging, Beijing, 100190, China
| | - Ke Tan
- Educational Technology Center, The Chinese PLA General Hospital, 100853, Beijing, China
| | - Zhifei Dai
- Department of Biomedical Engineering, College of Engineering, Peking University, Beijing, 100871, China
| | - Zhen Cheng
- Molecular Imaging Program at Stanford (MIPS), Bio-X Program, Department of Radiology, Stanford University, CA, 94305-5344, USA.
| | - Jie Tian
- Key Laboratory of Molecular Imaging of Chinese Academy of Sciences, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China; Beijing Key Laboratory of Molecular Imaging, Beijing, 100190, China.
| |
Collapse
|